Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

Promising more appraisal capacity, NICE revives industry fee idea

Rising workload and shrinking budget making charges inevitable

- PMLiVE

Vernalis accepts £33m takeover offer from Ligand Pharma

Biotech buyout brings team of 70 scientists in Cambridge, UK

- PMLiVE

UDG Healthcare sells Aquilant after share drop

Sells the business for up to €23m to private equity firm

- PMLiVE

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

News from pharma, biotech and healthcare

- PMLiVE

Human Cell Atlas gets new UK funding

The project will allow researchers to define characteristics of single cell types

- PMLiVE

Can a post-Brexit UK stay aligned with Europe on clinical research?

There's still no guarantee the UK can keep in step with EU

- PMLiVE

FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo

Becomes the first drug approved to treat Sézary syndrome

- PMLiVE

Healthcare Comms news

Bmore creative renames, Kyne partners up with Agora and Oxford PharmaGenesis expands to Australia

- PMLiVE

ABPI hits out at ‘punitive’ UK medicines cost controls

Steep rise in charges an 'alarming signal' amid Brexit uncertainty

- PMLiVE

Pharma survey: No Brexit is the best option

But many believe a 'no deal' Brexit most likely outcome

- PMLiVE

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Firm relying on launch success in pressured US market

omnichannel

Omni-empathy

So, we’ve arrived. Our work has stepped beyond multichannel to omnichannel. We can be and in fact are everywhere, all the time. We are omni-present. We are God. Or are...

Page & Page Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links